Evidence for the involvement of TNF-α, IL-1β and IL-10 in the antinociceptive and anti-inflammatory effects of indole-3-guanylhydrazone hydrochloride, an aromatic aminoguanidine, in rodents. (25th April 2018)

• Record Type: Journal Article
• Authors: Sandes, Silvia M.S.; Heimfarth, Luana; Brito, Renan G.; Santos, Priscila L.; Gouveia, Daniele N.; Carvalho, Alexandra M.S.; Quintans, Jullyana S.S.; da Silva-Júnior, Edeildo F.; de Aquino, Thiago M.; França, Paulo H.B.; de Araújo-Júnior, João X.; Albuquerque-Júnior, Ricardo L.C.; Zengin, Gokhan; Schmitt, Martine; Bourguignon, Jean-Jacques; Quintans-Júnior, Lucindo J.
• Is Part Of: Chemico-biological interactions. Volume 286(2018)
• Page Start: 1
• Page End: 10
• Publication Date: 2018-04-25
• Subjects: Guanidine -- Indole -- Inflammation -- Pain -- c-Fos -- Antioxidant; Biochemistry -- Periodicals; Toxicological chemistry -- Periodicals; Biochemistry -- Periodicals; Biologie moléculaire -- Périodiques; Biochimie -- Périodiques; Toxicologie biochimique -- Périodiques; 572
• DOI: 10.1016/j.cbi.2018.02.026
• Languages: English
• ISSNs: 0009-2797

Abstract

Abstract: Background: Indole-3-guanylhydrazone hydrochloride (LQM01) is a new derivative of aminoguanidine hydrochloride, an aromatic aminoguanidine. Methods: Mice were treated with LQM01 (5, 10, 25 or 50 mg/kg, i.p.), vehicle (0.9% saline i.p.) or a standard drug. The mice were subjected to carrageenan-induced pleurisy, abdominal writhing induced by acetic acid, the formalin test and the hot-plate test. The model of non-inflammatory chronic muscle pain induced by saline acid was also used. Mice from the chronic protocol were assessed for withdrawal threshold, muscle strength and motor coordination. LQM01 or vehicle treated mice were evaluated for Fos protein. Results: LQM01 inhibits TNF-α and IL-1β production, as well as leukocyte recruitment during inflammation process. The level of IL-10 in LQM01-treated mice increased in pleural fluid. In addition, LQM01 decreased the nociceptive behavior in the acetic acid induced writhing test, the formalin test (both phases) and increased latency time on the hot-plate. LQM01 treatment also decreased mechanical hyperalgesia in mice with chronic muscle pain, with no changes in muscle strength and motor coordination. LQM01 reduced the number of Fos positive cells in the superficial dorsal horn. This compound exhibited antioxidant properties in in vitro assays. Conclusions: LQM01 has an outstanding anti-inflammatory and analgesic profile, probably mediated through a reduction in proinflammatory cytokines release, increase in IL-10 production and reduction in neuron activity in the dorsal horn of the spinal cord in mice. General significance: Beneficial effects of LQM01 suggest that it has some important clinical features and can play a role in the management of 'dysfunctional pain' and inflammatory diseases. Graphical abstract: Highlights: LQM01 has an outstanding anti-inflammatory, analgesic and antioxidante profile. LQM01 inhibits TNF-α, IL-1β production and leukocyte recruitment during inflammation. LQM01 anti-inflammatory activity is associated to increased IL-10 levels. LQM01 decreased the nociceptive behavior in animals models of acute and chronic pain. LQM01 produce central analgesia, showing by decreased Fos protein in the spinal cord.